In today’s episode, David Flores sits down with Dr. Ryan Westrum, the founder and visionary of Healing Souls, a practice dedicated to changing the way individuals, couples and families look at counseling.
Similar Posts
The Spotlight Round Up Video, April 14th
In this week’s episode of The Spotlight Roundup, we check in with the Fireside Project, the first-ever 24/7 psychedelic peer support line; the State of Oregon forms an advisory board to oversee the implementation of psilocybin use in specialized clinics; and The American Journal of Psychiatry publishes new guidance on how to safety and effectively use Ketamine and Esketamine.
5 MeO-DMT: Throwing the Grenade into the Lake of Your Subconscious Mind with Tandava Retreats
In this episode of the Psychedelic Spotlight podcast, Swati sits…
Interview With Henri Sant-Cassia
In today’s episode of the Psychedelic Spotlight podcast, we spotlight Henri Sant-Cassia, Co-Founding Partner of The Conscious Fund, a leading investment fund in the medicinal psychedelics industry, focused on early stage ventures and psychedelic medicine that are helping to deliver better outcomes for mental health, addiction and pain.
Interview With Tesla La Touche
In this episode of the Psychedelic Spotlight podcast, we spend some time with Tesla La Touche who is the Founder and CEO of Aphrodite Health, the first ever female-founded biotech company within the medicinal psychedelic industry.
MindMed Facing Competition From HAVN? Plus Financials and Phase 2 Trials (MNMD, CYBIN, HAVN, MYCO)
Hey guys! In this week’s industry specific news, we’ll cover some interesting developments for MindMed, Mydecine, Cybin, HAVN, and a private company called WAKE. One of the biggest highlights is that HAVN might enter in direct competition with MindMed by penetrating the cluster headaches market. Stay tuned till the end the hear more on this specific news!
Timestamps:
0:00 – Intro
1:00 – MindMed Begins a Mescaline Study
4:35 – MindMed & The Chopra Foundation
8:30 – Cybin Progresses Phase 2a psilocybin study
11:56 – Mydecine announces Q1 Financials
14:16 – Havn Life Sciences enters the Cluster Headaches Game
16:30 – Wake Receives First-Ever Approval for Psilocybin for Anxiety & Depression
Enjoy!
Links:
MindMed (MNMD/ MMED / MMQ)) Begins a Mescaline Study:
https://mindmed.co/news/press-release/mindmed-announces-the-approval-of-mescaline-study/
MindMed Partners Up with The Chopra foundation:
https://mindmed.co/news/press-release/the-chopra-foundation-and-mindmed-enter-into-letter-of-intent-to-partner-on-the-future-of-psychedelic-medicines-mental-wellbeing/
Cybin (CYBN) Progresses Phase IIa psilocybin film strip study:
https://www.clinicaltrialsarena.com/news/cybin-phase-ii-psilocybin/
Mydecine (MYCO / MYCOF) Q1 Financials:
https://psilocybinalpha.com/news/mydecine-reports-first-quarter-2021-financial-results-and-provides-business-update
Havn Life Sciences (HAVN/ HAVLF/ 5NP) Begins to Study Cluster Headaches
https://havnlife.com/havn-life-enters-into-agreement-to-acquire-clinical-stage-ip-for-development-of-lsd-derived-api-for-cluster-headaches/
Wake Receives First-Ever Approval for Psilocybin Microdose Study for Anxiety and Depression
https://psychedelicspotlight.com/wake-psilocybin-microdose-study/
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
Video editing: @themyaholy
https://benzinga.grsm.io/jameshallifa…
https://benzinga.grsm.io/thepsychedel…
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #PsychedelicStocks #HAVN
Will MindMed Partner With Johnson & Johnson for 18MC? ( MNMD & J&J In the Speculation Zone)
What’s up Psychedelic Investors? We all know that MindMed (MNMD / MMED) has been talking about eventually finding partners in the pharmaceuticals industry, but who will be that partner? One persistent Reddit theory posits that it will be none other than Johnson & Johnson. Could this just be a rumor? Perhaps. But depending on how you look at it, there is either some evidence for this theory…or some coincidences.
MindMed is a psychedelic medicines/psychedelic therapy company that is attempting to treat addiction, depression, anxiety and more with LSD, psilocybin (magic mushrooms), 18MC, and other psychedelics. But in order to scale up, they may need the expertise and global reach of a company like JNJ.
MindMed stock (MNMD / MMED) has been quiet for a while now, could a partnership with JNJ be exactly what the company needs? Will MindMed stock go up? Is MindMEd a good investment? Only time will tell!
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #JNJ #MNMD